Invest In Biomed is a unique Eurobiomed program that helps innovative healthcare companies consolidate their fund-raising approach and tools, and introduces them to specialized investors in the sector. To mark the launch of the 10e edition of this program, we give the floor to entrepreneurs who have benefited from it.
Amaury Ciurana, CEO and co-founder of REEV, looks back on his experience of Eurobiomed's Invest In Biomed program, which supports healthcare start-ups in their financing and fundraising strategy. His company, which develops a lightweight, intelligent motorization system for medical orthoses that makes daily mobility easier, took part in the program in 2022, before raising a first round of €3 million in 2023, followed by a second round of €8.8 million in early 2025.
What have been the concrete results of your participation in the Invest In Biomed program?
Amaury Ciurana: Taking part in the fin 2022 program was an important step in our financing process. In particular, we met one of our future investors, who a few months later became the lead investor in our first round of financing in early 2023.
This initial meeting marked the beginning of a long-lasting collaboration, as this investor continues to accompany us as lead investor in our development, notably during our second round of financing in early 2025.
How did you go about preparing for your fund-raising campaign?
Amaury Ciurana: The Eurobiomed team supported us through several working sessions dedicated to preparing and optimizing our fund-raising strategy. This preparation phase culminated in a presentation in Marseille to a panel of investors, which was particularly well received.
Although our presentation has naturally evolved since then, the strategy and mission we defined back then have remained the same, demonstrating the relevance of the work we've done.
What do you see as the program's main added value?
Amaury Ciurana: Invest In Biomed's real strength lies in its ability to create an environment conducive to building trusting relationships with investors. The program offers a structured framework where entrepreneurs can present their project in person, which is becoming increasingly rare in today's fund-raising processes.
It provides an opportunity to meet investors who are already familiar with the healthcare sector, and who recognize the added value of Eurobiomed's selection process. From there, it's up to the entrepreneur to build on these initial connections, as we've successfully done.
SIMILAR ARTICLES :
Arnaud Debains and Sandrine Isz (BOYDSense): "Invest In Biomed helped us tell our story better".
Philippe Andres (Tarian Pharma): "Invest In Biomed's support enabled us to adapt our language to that of investors".
